Fidelis Capital Partners LLC Has $1.22 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Fidelis Capital Partners LLC lifted its stake in shares of Danaher Co. (NYSE:DHR) by 38.2% during the fourth quarter, Holdings Channel reports. The firm owned 5,259 shares of the conglomerate’s stock after purchasing an additional 1,453 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Danaher were worth $1,217,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. BKM Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter worth $27,000. OFI Invest Asset Management purchased a new position in shares of Danaher during the third quarter valued at $30,000. First Capital Advisors Group LLC. acquired a new position in Danaher during the second quarter valued at $32,000. BOK Financial Private Wealth Inc. acquired a new position in Danaher during the third quarter valued at $34,000. Finally, Nalls Sherbakoff Group LLC acquired a new position in Danaher during the third quarter valued at $37,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,957 shares of company stock valued at $8,265,802. Insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Royal Bank of Canada upped their price target on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. JPMorgan Chase & Co. upped their price target on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, December 20th. KeyCorp upped their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Raymond James upped their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Finally, Citigroup upped their price target on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $268.27.

Danaher Stock Down 1.3 %

Shares of NYSE DHR traded down $3.02 during mid-day trading on Thursday, reaching $236.37. 4,261,040 shares of the company traded hands, compared to its average volume of 2,727,856. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.68. The stock has a market cap of $175.04 billion, a PE ratio of 37.46, a price-to-earnings-growth ratio of 3.65 and a beta of 0.83. The company’s fifty day moving average is $249.28 and its two-hundred day moving average is $229.86. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The business had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The firm’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.87 EPS. On average, analysts expect that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. Danaher’s dividend payout ratio is currently 16.90%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.